 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- IMP9064 / IMPACT Therap
Discovery and development of a potent and highly selective ATR inhibitor IMP9064 (Section 15; Poster Board No: 20) - Mar 25, 2025 - Abstract #AACR2025AACR_6844;
P1/2
IMP9064 has entered a phase 1/2 study to evaluate the safety and efficacy either as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT05269316). The recommended phase 2 dose (RP2D) has been determined and IMP9064 is currently in expansion studies for selected tumors.
- | IMP9064 / IMPACT Therap, Paxonin (senaparib) / IMPACT Therap
Phase classification, Monotherapy: Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 22, 2024
P1, N=61, Recruiting, Sponsor: Impact Therapeutics, Inc.
The recommended phase 2 dose (RP2D) has been determined and IMP9064 is currently in expansion studies for selected tumors. Phase classification: P1/2 --> P1
- IMP9064 / IMPACT Therap, senaparib (IMP4297) / IMPACT Therap
First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2254;
P1/2
Conclusions These results indicate that IMP9064 monotherapy appears to be well-tolerated and support further dose escalation. More MRD and biomarker analyses are underway.
- |||| IMP9064 / IMPACT Therap, Paxonin (senaparib) / IMPACT Therap
New P1/2 trial, Monotherapy: Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 7, 2022
P1/2, N=61, Recruiting, Sponsor: Impact Therapeutics, Inc.